Digital Look

Welcome to Digital Look++,
you are not logged in

Avacta Group (AVCT)

Pharma and Biotech

Trade now with Barclays Stockbrokers Sponsored by Barclays Stockbrokers

22.25p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
31-Jan-19	Interim	0.97	(5.85)	(4.80)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Jul-14	1.62	(2.02)	(4.00)p	n/a	n/a	n/a	n/a	0.0%
31-Jul-15	1.81	(5.54)	(5.00)p	n/a	n/a	n/a	n/a	0.0%
31-Jul-16	2.17	(5.57)	(6.86)p	n/a	n/a	n/a	n/a	0.0%
31-Jul-17	2.73	(7.89)	(9.77)p	n/a	n/a	n/a	n/a	0.0%
31-Jul-18	2.76	(10.39)	(13.49)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Jul-19	3.10	(12.10)	(9.10)p	n/a	n/a	n/a	n/a	0.0%
31-Jul-20	4.38	(11.38)	(8.30)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.